cad3-marburg vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2018 (NCT03475056)
Timeline
Indications
Mechanism of action
- MarburgvirusImmunity, active
Marburgvirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06620003 | Phase 2 | Jan 31, 2025 | Albert B. Sabin Vaccine Institute, Department of Health and Human Services |
| NCT05817422 | Phase 2 | Sep 25, 2023 | Albert B. Sabin Vaccine Institute, Department of Health and Human Services |
| NCT04723602 | Phase 1 | Jan 6, 2021 | Albert B. Sabin Vaccine Institute, ICON, Oklahoma Blood Institute |
| NCT03475056 | Phase 1 | Mar 31, 2018 | National Institute of Allergy and Infectious Diseases (NIAID), United States Army |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Albert B. Sabin Vaccine Institute | Academic/Hospital | 3 | 3 | 2 | 2021 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2023 |
| ICON | For profit | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2018 |
| Oklahoma Blood Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| United States Army | Government | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1